Raymond Tan, MD
Radiation Oncology · Fresno, CANPI 1104809946
Payments from drug & device makers
Across 54 payments — averaging $25.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$322
- E.r. Squibb & Sons, L.L.C.$194
- Boston Scientific$101
- Bayer$61
- Stemline Therapeutics Inc.$59
- Regeneron Healthcare Solutions, Inc.$53
- plus $570 from 21 others
What the payments were for
- Food & beverage$1,361100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $322 |
| E.r. Squibb & Sons, L.L.C. | 12 | $194 |
| Boston Scientific | 3 | $101 |
| Bayer | 3 | $61 |
| Stemline Therapeutics Inc. | 2 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| Sumitomo Pharma America, Inc. | 2 | $51 |
| Novocure Inc. | 2 | $51 |
| Exelixis Inc. | 2 | $42 |
| Johnson & Johnson | 2 | $40 |
| Sobi, Inc | 1 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Merck | 1 | $28 |
| Pfizer | 1 | $25 |
| Siemens Medical Solutions USA, Inc. | 1 | $24 |
| Genmab U.S., Inc. | 1 | $24 |
| AbbVie | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $24 |
| Novartis | 1 | $23 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Myriad Genetic Laboratories, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Palette Life Sciences, Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| GSK | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$125
How this compares
$1,361 in reported general payments places this provider in the 65th percentile of 627 radiation oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pilocarpine Hcl | 27 | $1,741 |
| Tamsulosin Hcl | 32 | $814 |
| Lidocaine Hcl ViscousLidocaine Hcl | 21 | $321 |
| Oxycodone Hcl | 15 | $206 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $175 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Fresno
- Loren Mellla Jolla$10M
- Hyun KimDuarte$6M
- Megan DalyOrange$4.5M
- Percy LeeIrvine$2.4M
- Felix FengSan Francisco$1.8M
- Jeffrey WongDuarte$1.7M
- Arta MonjazebSacramento$1.5M
- Rakesh PatelLos Gatos$1.3M
- Maximilian DiehnStanford$1.2M
- Rizwan NuraniApple Valley$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.